Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2017-04-27 Management Reports
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
2016年度独立董事述职报告
Management Reports Classification · 95% confidence The document is titled as the "2016年度独立董事述职报告" which translates to "2016 Annual Independent Director's Work Report." It contains detailed descriptions of the independent directors' attendance at board meetings and shareholders' meetings, their independent opinions on various company matters, their committee work, on-site investigations, and efforts to protect shareholders' rights. The content focuses on the directors' duties, opinions, and governance activities rather than financial results or audit opinions. It is a report by the independent directors on their work and oversight during the year, which is a form of management or governance reporting. It is not an annual report (10-K), audit report (AR), or earnings release (ER). It is not a proxy statement or voting results announcement. The document is substantive and lengthy (over 11,000 characters), so it is not a mere announcement or certification. Given the focus on directors' duties and governance oversight, the best fitting category is "Management Reports (MDA)" which covers management's detailed explanation of business trends, governance, and outlook, including directors' reports on their activities.
2017-04-27 Chinese
关于募集资金年度存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the annual storage and usage of raised funds by the company 葵花药业集团股份有限公司. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, includes specific financial figures related to fundraising, usage, and balances as of December 31, 2016, and contains tables showing the use and changes in investment projects funded by the raised capital. The document is not a brief announcement but a substantive report with financial data and compliance details. It is not an annual report, earnings release, or management discussion but a specialized report focused on the management and use of fundraising proceeds. This matches the description of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital usage.
2017-04-27 Chinese
东海证券股份有限公司关于公司首次公开发行股票之保荐总结报告书
Audit Report / Information Classification · 95% confidence The document is titled as a "保荐总结报告书" which translates to "Sponsorship Summary Report" related to the initial public offering (IPO) of a company. It details the continuous supervision and sponsorship activities by the securities firm during the IPO process and subsequent monitoring period until 2016. It includes information about due diligence, compliance with regulations, review of annual reports, governance, and use of raised funds. The document is not an annual report, earnings release, or a regulatory filing announcement but a detailed summary report of the sponsorship and supervision activities related to the IPO. This type of document is best classified under Audit Report / Information (AR) as it involves audit-like oversight and reporting on compliance and due diligence related to the IPO and ongoing supervision. FY 2016
2017-04-27 Chinese
东海证券股份有限公司关于公司内部控制规则落实自查表的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from Donghai Securities regarding the internal control self-assessment form of Kuihua Pharmaceutical Group Co., Ltd. It references regulatory guidelines related to securities issuance and listing sponsorship. The document is short (725 characters) and primarily provides an opinion on the internal control self-assessment, not the full audit or internal control report itself. It does not contain detailed financial data or comprehensive audit results. It is essentially a regulatory compliance verification statement by the sponsor. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for compliance documents and attestation letters that do not constitute full reports.
2017-04-27 Chinese
关于续聘2017年度财务审计机构的公告
Audit Report / Information Classification · 90% confidence The document is an announcement regarding the reappointment of the financial audit firm for the fiscal year 2017. It mentions the board meeting resolutions and independent directors' opinions approving the reappointment of the audit firm. The document does not contain any financial statements or audit reports themselves but is a formal announcement of the decision to continue the audit engagement. The document length is short (980 characters), and it serves as a notice rather than the audit report or annual report itself. Therefore, it fits best under Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or audit report document. FY 2017
2017-04-27 Chinese
关于公司2017年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the expected related party transactions for the year 2017. It details the nature of the transactions, the parties involved, pricing policies, and includes opinions from independent directors and the supervisory board. The document is relatively short (2942 characters) and focuses on disclosure of anticipated related party transactions rather than presenting financial statements or comprehensive financial performance data. It is not an annual report, interim report, earnings release, or any detailed financial report. It is also not a voting result, management change, or legal proceeding. The content fits the category of a Regulatory Filing (RNS) as it is a regulatory disclosure announcement about related party transactions, which does not fit into more specific categories like Annual Report or Capital Update. Therefore, the best classification is Regulatory Filings (RNS).
2017-04-27 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.